Toll Free: 1-888-928-9744

Dr. Falk Pharma GmbH - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Dr. Falk Pharma GmbH - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Dr. Falk Pharma GmbH - Product Pipeline Review - 2014', provides an overview of the Dr. Falk Pharma GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dr. Falk Pharma GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Dr. Falk Pharma GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Dr. Falk Pharma GmbH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Dr. Falk Pharma GmbH's pipeline products

Reasons to buy

- Evaluate Dr. Falk Pharma GmbH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Dr. Falk Pharma GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Dr. Falk Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Dr. Falk Pharma GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dr. Falk Pharma GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Dr. Falk Pharma GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Dr. Falk Pharma GmbH Snapshot 5
Dr. Falk Pharma GmbH Overview 5
Key Information 5
Key Facts 5
Dr. Falk Pharma GmbH - Research and Development Overview 6
Key Therapeutic Areas 6
Dr. Falk Pharma GmbH - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Dr. Falk Pharma GmbH - Pipeline Products Glance 13
Dr. Falk Pharma GmbH - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Dr. Falk Pharma GmbH - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Dr. Falk Pharma GmbH - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Dr. Falk Pharma GmbH - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Dr. Falk Pharma GmbH - Drug Profiles 18
budesonide 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
LT-02 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
mesalamine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
rifamycin 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
norursodeoxycholic acid 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
udenafil 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RhuDex 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ZED-1227 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ZED-101 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Dr. Falk Pharma GmbH - Pipeline Analysis 33
Dr. Falk Pharma GmbH - Pipeline Products by Target 33
Dr. Falk Pharma GmbH - Pipeline Products by Route of Administration 34
Dr. Falk Pharma GmbH - Pipeline Products by Molecule Type 35
Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action 36
Dr. Falk Pharma GmbH - Recent Pipeline Updates 37
Dr. Falk Pharma GmbH - Dormant Projects 41
Dr. Falk Pharma GmbH - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
CNDO-201 42
mesalamine 42
Dr. Falk Pharma GmbH - Locations And Subsidiaries 43
Head Office 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45
List of Tables
Dr. Falk Pharma GmbH, Key Information 5
Dr. Falk Pharma GmbH, Key Facts 5
Dr. Falk Pharma GmbH - Pipeline by Indication, 2014 8
Dr. Falk Pharma GmbH - Pipeline by Stage of Development, 2014 9
Dr. Falk Pharma GmbH - Monotherapy Products in Pipeline, 2014 10
Dr. Falk Pharma GmbH - Partnered Products in Pipeline, 2014 11
Dr. Falk Pharma GmbH - Partnered Products/ Combination Treatment Modalities, 2014 12
Dr. Falk Pharma GmbH - Pre-Registration, 2014 13
Dr. Falk Pharma GmbH - Phase III, 2014 14
Dr. Falk Pharma GmbH - Phase II, 2014 15
Dr. Falk Pharma GmbH - Preclinical, 2014 16
Dr. Falk Pharma GmbH - Unknown, 2014 17
Dr. Falk Pharma GmbH - Pipeline by Target, 2014 33
Dr. Falk Pharma GmbH - Pipeline by Route of Administration, 2014 34
Dr. Falk Pharma GmbH - Pipeline by Molecule Type, 2014 35
Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action, 2014 36
Dr. Falk Pharma GmbH - Recent Pipeline Updates, 2014 37
Dr. Falk Pharma GmbH - Dormant Developmental Projects,2014 41
Dr. Falk Pharma GmbH - Discontinued Pipeline Products, 2014 42 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify